NCT01548417

Brief Summary

The primary hypotheses under test are that alcohol dependent subjects treated with mifepristone will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
56

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Mar 2012

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

March 5, 2012

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 8, 2012

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2015

Completed
11 months until next milestone

Results Posted

Study results publicly available

May 19, 2016

Completed
Last Updated

June 24, 2016

Status Verified

May 1, 2016

Enrollment Period

3.3 years

First QC Date

March 5, 2012

Results QC Date

February 2, 2016

Last Update Submit

May 24, 2016

Conditions

Keywords

AlcoholRelapse

Outcome Measures

Primary Outcomes (1)

  • Craving to Drink

    Visual Analog Scale (VAS) scores of craving severity in response to in vivo alcohol cues. Higher scores indicate greater craving severity with a minimum score of 0 and a maximum score of 80.

    1 week

Secondary Outcomes (1)

  • Drinking

    2 weeks

Study Arms (2)

Korlym (mifepristone)

ACTIVE COMPARATOR

600 mg daily taken orally for one week

Drug: Korlym (mifepristone)

Sugar Pill

PLACEBO COMPARATOR

placebo pill daily taken orally for one week

Drug: Sugar Pill

Interventions

600 mg/day, oral pill, 7 days

Also known as: Mifepristone, C-1073, Mifeprex, RU-486
Korlym (mifepristone)

600 mg/day, oral pill, 7 days

Also known as: Placebo
Sugar Pill

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female volunteers, 18-65 years of age
  • Meets Diagnostic and Statistical Manual of Mental Disorders Fourth Addition (DSM-IV) criteria for current alcohol dependence
  • Subjects will not be seeking treatment because the medication studies are not treatment trials
  • Subjects must be abstinent a minimum of 3 days (but not more than 7 days) prior to the human lab session
  • Negative Breath Alcohol Concentration (BAC) and a Clinical Institute Withdrawal Assessment-Alcohol (CIWA-A) score of \< 8 at screening and time of lab session to eliminate acute alcohol or withdrawal effects on dependent measures
  • Subjects must be able to complete and understand questionnaires and study procedures in English and sign an informed consent

You may not qualify if:

  • Significant medical disorders that will increase potential risk or interfere with study participation as determined by the Study Physician
  • Female subjects with childbearing potential who are pregnant, nursing, or refuse to use double barrier (non-hormonal) methods of birth control for the duration of the study and one month thereafter
  • Meets DSM-IV criteria for a major Axis I disorder including mood or anxiety disorders or substance dependence disorders other than alcohol or nicotine dependence
  • History of allergy or hypersensitivity to the study drugs or the ingredients
  • Treatment within the month prior to screening with 1.) an investigational drug or vaccine; 2.) drugs that may influence study outcomes, e.g., disulfiram (Antabuse), naltrexone (ReVia), acamprosate (Campral), anticonvulsants, antidepressants.
  • In need of or currently taking any psychoactive medications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Scripps Research Institute

La Jolla, California, 92037, United States

Location

Related Publications (1)

  • Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, McGinn MA, Zamora-Martinez ER, Belanoff JK, Hunt HJ, Sanna PP, George O, Koob GF, Edwards S, Mason BJ. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest. 2015 Aug 3;125(8):3193-7. doi: 10.1172/JCI79828. Epub 2015 Jun 29.

Related Links

MeSH Terms

Conditions

AlcoholismRecurrence

Interventions

MifepristoneSugars

Condition Hierarchy (Ancestors)

Alcohol-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental DisordersDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

EstrenesEstranesSteroidsFused-Ring CompoundsPolycyclic CompoundsCarbohydrates

Results Point of Contact

Title
Barbara J. Mason, Ph.D.
Organization
The Scripps Research Institute

Study Officials

  • Barbara J Mason, PhD

    The Scripps Research Institute

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PI

Study Record Dates

First Submitted

March 5, 2012

First Posted

March 8, 2012

Study Start

March 1, 2012

Primary Completion

July 1, 2015

Study Completion

July 1, 2015

Last Updated

June 24, 2016

Results First Posted

May 19, 2016

Record last verified: 2016-05

Data Sharing

IPD Sharing
Will not share

Locations